Mölnlycke Health Care and Transdiagen announce research collaboration to drive innovation in wound care

GOTHENBURG, Sweden, October 24, 2024 /PRNewswire/ — Today, Mölnlycke Health Care, a world-leading medical technology company specializing in wound care and treatment, announces a research collaboration with Transdiagen (TDG), a precision medicine company developing medicines and diagnostics for wound healing. chronic wounds and tissue regeneration. The collaboration aims to utilize TDG’s novel wound genetic signatures to further explore Mölnlycke products.

Emma Wright, Executive Vice President Medical at Mölnlycke, commented: “We are excited about our research collaboration with TDG, which allows us to be at the forefront of advanced understanding of chronic wounds. This opens up a wealth of opportunities for future innovation in regional with few resources and a priority area of ​​wound care.”

James Harding, CEO of Transdiagen added: “We are excited to be working with Mölnlycke on this R&D program. This collaboration will enable Mölnlycke to access TDG’s new models to generate functional insights into the mode of action of innovative, biological wound care solutions . We believe this marks a new chapter in the approach to data-driven, evidence-based product development for the treatment of complex wounds.”

The collaboration will begin soon.

For more information, contact:

Jennifer Doak

Director of Global Communications for Wound Care
Email: [email protected]

Telephone: +1 678 206 6179

This information is brought to you by Cision http://news.cision.com

https://news.cision.com/molnlycke/r/molnlycke–health-care-and-transdiagen-announce-research-collaboration-to-drive-innovation-in-wound-,c4056056

The following files are available for download:

View original content: https://www.prnewswire.co.uk/news-releases/molnlycke-health-care-and-transdiagen-announce-research-collaboration-to-drive-innovation-in-wound-care-302286130 . HTML